Pharmacogenomic Germline Testing: Applications in Oncology Nursing

被引:0
|
作者
Germany, Joshua [1 ]
Kueber, Janet [1 ]
机构
[1] Prisma Hlth Canc Inst Greenville, Greenville, SC 29615 USA
关键词
pharmacogenomics; pharmacogenetics; germline testing; precision medicine; FUTURE;
D O I
10.1188/23.CJON.129-133
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The implementation of pharmacogenomics in clinical practice has increased in clinical oncology practice. Pharmacogenomic germline testing can be used to develop and prescribe safer and more effective medications and treatment regimens that are personalized to patients based on their individual genetic profiles. To properly apply pharmacogenomics to oncology practice, nurses need to have a clear understanding of pharmacogenomics, specifically how to collect DNA specimens, interpret test results, and educate patients about lifelong implications. This article reviews pharmacogenomic germline testing, its use in oncology clinical practice, and how pharmacogenomics can help oncology nurses provide optimal care for patients.
引用
收藏
页码:129 / 133
页数:5
相关论文
共 50 条
  • [31] Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
    Vivot, Alexandre
    Boutron, Isabelle
    Beraud-Chaulet, Geoffroy
    Zeitoun, Jean-David
    Ravaud, Philippe
    Porcher, Raphael
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [32] Oncology Nursing Society (ONS): The use of nursing diagnoses in oncology nursing practice
    Carroll-Johnson, RM
    [J]. CLASSIFICATION OF NURSING DIAGNOSES, PROCEEDINGS, 1999, : 244 - 246
  • [33] ONCOLOGY NURSING
    HASSELS, A
    [J]. AMERICAN JOURNAL OF NURSING, 1976, 76 (02) : 208 - 208
  • [34] Oncology Nursing
    Gibson, Samantha
    [J]. CANCER FORUM, 2008, 32 (03)
  • [35] Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing
    Alexandre Vivot
    Isabelle Boutron
    Geoffroy Béraud-Chaulet
    Jean-David Zeitoun
    Philippe Ravaud
    Raphaël Porcher
    [J]. Scientific Reports, 7
  • [36] Adoption of Pharmacogenomic Testing: A Marketing Perspective
    Koufaki, Margarita-Ioanna
    Karamperis, Kariofyllis
    Vitsa, Polixeni
    Vasileiou, Konstantinos
    Patrinos, George P.
    Mitropoulou, Christina
    [J]. FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [37] Erlotinib and patterns of pharmacogenomic (PGx) testing
    De Souza, Jonas A.
    Gleason, Patrick P.
    Starner, Catherine I.
    Qiu, Yang P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (34)
  • [38] Pharmacogenomic Testing and Personalized Treatment of Depression
    Perlis, Roy H.
    [J]. CLINICAL CHEMISTRY, 2014, 60 (01) : 53 - 59
  • [39] The challenges of implementing pharmacogenomic testing in the clinic
    Moyer, Ann M.
    Caraballo, Pedro J.
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2017, 17 (06) : 567 - 577
  • [40] Misleading Guidance From Pharmacogenomic Testing
    Rahman, Tahir
    Ash, David M.
    Lauriello, John
    Rawlani, Roshni
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2017, 174 (10): : 922 - 924